SHARE-BASED PAYMENTS

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

SHARE-BASED PAYMENTS

The Company, under the 2018 Amended and Restated Omnibus Equity Incentive Compensation Plan (the “Equity Incentive Plan”), maintains an equity incentive plan for directors, executives, eligible employees and consultants. Equity incentive awards include employee stock options, restricted stock units (“RSUs”) and stock appreciation rights (“SARs”). The Company issues new shares of common stock to satisfy exercises and vesting under all of its equity incentive awards. At December 31, 2020, a total of 13,431,103 Common Shares were authorized for equity incentive plan awards.

Employee Stock Options

The Company, under the Equity Incentive Plan, may grant options to directors, executives, employees and consultants to purchase Common Shares of the Company. The exercise price of the options is set as the higher of the Company’s closing share price on the day before the grant date or the five-day volume weighted average price (“VWAP”). Stock options granted under the Equity Incentive Plan generally vest over a period of two years or more and are generally exercisable over a period of five years from the grant date not to exceed 10 years. The value of each option award is estimated at the grant date using the Black-Scholes Option Valuation Model. There were 0.71 million options granted in the year ended December 31, 2020 (December 31, 2019 – 0.30 million, December 31, 2018 - 0.42 million). At December 31, 2020, there were 1.61 million options outstanding with 1.21 million options exercisable, at a weighted average exercise price of $2.91 and $3.23 respectively, with a weighted average remaining contractual life of 2.75 years and 2.44 years, respectively. The aggregate intrinsic value of the fully vested shares was $1.80 million.

The summary of the Company’s stock options at December 31, 2020, 2019 and 2018, respectively, and the changes for the fiscal periods ending on those dates are presented below:


	Range of Exercise Prices	Weighted Average Exercise Price		Number of Options
Balance, December 31, 2017	$1.77 - $15.61	$	4.48	2,028,847
Granted	1.70 - 2.88	1.75		442,956
Exercised	1.70 - 2.55	2.15		(355,092)
Forfeited	1.70 - 6.63	3.96		(213,393)
Expired	5.86 - 10.36	8.18		(170,564)
Balance, December 31, 2018	$1.70 - $15.61	$	3.84	1,732,754
Granted	2.92	2.92		296,450
Exercised	1.70 - 2.92	2.27		(54,805)
Forfeited	1.70 - 7.42	3.94		(342,866)
Expired	6.97	6.97		(144,100)
Balance, December 31, 2019	$1.70 - $15.61	$	3.43	1,487,433
Granted	1.76 - 3.06	1.77		711,414
Exercised	1.70 - 2.92	1.97		(302,707)
Forfeited	1.70 - 5.18	3.26		(188,541)
Expired	4.12 - 5.22	4.40		(98,512)
Balance, December 31, 2020	$1.70 - $15.61	$	2.91	1,609,087

As of December 31, 2020, the outstanding stock options denominated in USD$ were as follows:


	Options Outstanding						Options Exercisable
Exercise price	Quantity	Weighted Average Price		Weighted Average Remaining Contractual Life	Intrinsic Value		Quantity	Weighted Average Price		Weighted Average Remaining Contractual Life	Intrinsic Value
$— to $4.99	1,449,587	$	2.41	2.91	$	2,731	1,045,597	$	2.59	2.61	$	1,803
$5.00 to $9.99	133,235	$	6.16	1.52	—		133,235	6.16		1.52	—
$10.00 to $14.99	13,515	$	12.59	0.27	—		13,515	12.59		0.27	—
$15.00 to $19.99	12,750	$	15.61	0.03	—		12,750	$	15.61	0.03	—
	1,609,087				$	2,731	1,205,097				$	1,803

In the year ended December 31, 2020, the Company issued 302,707 shares upon exercise of stock options at an average exercise price of $1.97 for proceeds of $0.49 million. These options had an intrinsic value of $0.42 million.

In the year ended December 31, 2019, the Company issued 54,805 shares upon exercise of stock options at an average exercise price of $2.27 for proceeds of $0.15 million. These options had an intrinsic value of $0.05 million.

In the year ended December 31, 2018, the Company issued 355,092 shares upon exercise of stock options at an average exercise price of $2.15 for proceeds of $0.76 million. These options had an intrinsic value of $0.41 million.

The share-based compensation recorded during the years ended December 31, 2020, 2019 and 2018 are as follows:


	Years ended December 31,
	2020		2019		2018
Share-based compensation (1)(2)	$	2,598	$	3,771	$	2,762

(1)The fair value of the options granted under the Equity Incentive Plan for the years ended December 31, 2020, 2019 and 2018 was estimated at the date of grant, using the Black-Scholes Option Valuation Model, with the following weighted average assumptions:


	Years ended December 31,
	2020			2019				2018
Risk-free interest rate	1.27		%	2.62		%		2.84		%
Expected life	4.6 years			5.0 years				5.0 years
Expected volatility	61.81		%	59.38		%	*	59.00		%	*
Expected dividend yield	0		%	0		%		0		%
Weighted average grant date fair value	$	0.82		$	1.54			$	0.96

* Expected volatility is measured based on the Company’s historical share price volatility over a period equivalent to the expected life of the options.

(2)The fair value of the RSUs granted under the Equity Incentive Plan for the years ended December 31, 2020, 2019 and 2018, was estimated at the date of grant, using the stated market price.

A summary of the status and activity of non-vested stock options at December 31, 2020 is as follows:


	Number of Shares	Weighted Average Grant Date Fair Value
Non-vested December 31, 2017	365,180	$	1.20
Granted	442,956	0.96
Vested	(448,662)	1.10
Forfeited	(62,430)	0.96
Non-vested December 31, 2018	297,044	$	1.06
Granted	296,450	1.54
Vested	(356,626)	1.27
Forfeited	(13,487)	1.59
Non-vested December 31, 2019	223,381	$	1.32
Granted	711,414	0.82
Vested	(508,630)	0.94
Forfeited	(22,175)	0.96
Non-vested December 31, 2020	403,990	$	0.94

Restricted Stock Units

The Company grants RSUs to directors, executives and eligible employees. Awards are determined as a target percentage of base salary and generally vest over periods of three years. Prior to vesting, holders of restricted stock units do not have voting rights. The RSUs are subject to forfeiture risk and other restrictions. Upon vesting, the employee is entitled to receive one share of the Company’s common stock for each RSU for no additional payment. During the year ended December 31, 2020, the Company’s Board of Directors issued 0.74 million RSUs under the Equity Incentive Plan (2019 – 0.73 million, 2018 - 1.19 million).

A summary of the status and activity of non-vested RSUs at December 31, 2020 is as follows:


	Number of Shares	Weighted Average Grant Date Fair Value
Non-vested December 31, 2017	1,909,477	$	2.17
Granted	1,191,132	1.70
Vested	(1,486,126)	2.24
Forfeited	(34,296)	2.00
Non-vested December 31, 2018	1,580,187	$	1.99
Granted	731,435	2.91
Vested	(862,378)	2.00
Forfeited	(133,708)	2.40
Non-vested December 31, 2019	1,315,536	$	2.45
Granted	740,998	1.65
Vested	(746,477)	2.45
Forfeited	(216,001)	2.13
Non-vested December 31, 2020	1,094,056	$	1.98

The total intrinsic value and fair value of RSUs that vested and were settled for equity in the year ended December 31, 2020 was $1.21 million (2019 - $2.51 million, 2018 - $1.49 million).

Stock Appreciation Rights

During the year ended December 31, 2019, the Company’s Board of Directors issued 2.20 million SARs under the Equity Incentive Plan (2020 and 2018 - nil) with a fair value of $1.25 per SAR. These SARs are intended to provide additional long-term performance-based equity incentives for the Company’s senior management. The SARs are performance based, because they only vest upon the achievement of performance goals designed to significantly increase shareholder value.

Each SAR outstanding entitles the holder, on exercise, to a payment in cash or shares (at the election of the Company) equal to the difference between the market price of the Common Shares at the time of exercise and $2.92 (the market price at the time of grant) over a five-year period, but vest only upon the achievement of the following performance goals: as to one-third of the SARs granted upon the 90-calendar-day VWAP of the Common Shares on the NYSE American equaling or exceeding $5.00 for any 90-calendar-day period; as to an additional one-third of the SARs granted, upon the 90-calendar-day VWAP of the Common Shares on the NYSE American equaling or exceeding $7.00 for any 90-calendar-day period; and as to the final one-third of the SARs granted, upon the 90-dalendar-day VWAP of the Common Shares on the NYSE American equaling or exceeding $10.00 for any 90-calendar-day period. Further, notwithstanding the foregoing vesting schedule, no SARs may be exercised by the holder for an initial period of one year from the Date of Grant; the date first exercisable being January 22, 2020.

At December 31, 2020, there was $0.05 million, $0.55 million and $0.24 million of unrecognized compensation costs related to the unvested stock options, RSU awards and SARs, respectively. These costs are expected to be recognized over a period of approximately two years.